Key Highlights

  • Following results for a four-month transition period, FedEx Freight has advanced 14.61% to $125.72.
  • Record fiscal second-quarter Revenue of $656.4 million accompanies a 14.46% rise for Cavco Industries, now at $626.36.
  • Third-quarter revenue jumped 36% to $5.1 billion, and Regeneron Pharmaceuticals is up 14.21% at $935.14.
  • AutoNation added a $1.0 billion buyback authorization in October and sits 10.73% higher at $187.51.
  • Veralto lifted its full-year adjusted Earnings guidance to $4.49 to $4.52 per share, and its stock is up 8.97% at $113.39.

High-Priced Stocks Posting the Largest Percentage Gains Today

Five shares priced above $100 take the top spots among percentage gainers on Oct 30, 2026, ordered by size of move. FedEx Freight (NYSE:FDXF) leads with a 14.61% gain to $125.72. Cavco Industries (NASDAQ:CVCO) has risen 14.46% to $626.36, and Regeneron Pharmaceuticals (NASDAQ:REGN) has added 14.21%, reaching $935.14.

AutoNation (NYSE:AN) has advanced 10.73% to $187.51, and Veralto (NYSE:VLTO) has moved up 8.97% to $113.39. Each percentage is measured from that stock's prior close, so the reference points differ and a given move carries a different dollar weight from name to name.

Every company in this group has issued new financial results or guidance, and those disclosures are the most probable backdrop for the advances. Where valuation numbers come from earlier snapshots that predate today's move, the sections below say so, and they note where the tie between a report and the price jump rests on timing alone.

1. FedEx Freight: what makes the stock rise after its first standalone report?

Shares of FedEx Freight have gained 14.61% to $125.72 after the company released figures for a one-time transition period covering June 1 to Sept 30, 2026, four months in all. This is its first report since separating from FedEx (NYSE:FDX). Revenue rose 9.2% to $3.3 billion, aided by fuel surcharges, heavier shipments, an additional operating day and firmer base pricing, although average daily shipments dipped 1.4%.

Adjusted Operating Income climbed 16.4% to $510 million, a 15.5% margin, yet GAAP diluted EPS fell 43% to $1.54 because $127 million in spin-off costs weighed on the figure. Guidance for adjusted operating income through Dec 31, 2026 now stands at $695 million to $715 million, versus $605 million to $645 million previously.

North America's leading less-than-truckload carrier, the Business is valued near $18.7 billion, with a 52-week range of $103.48 to $200.00 in market data that may partly predate the move, so those numbers are approximate.

2. Cavco Industries: record quarterly revenue and an insurance refund in the mix

Cavco Industries, a Phoenix-based maker of manufactured homes, is up 14.46% at $626.36 after reporting fiscal second-quarter results for the period ended Sept 26, 2026. Revenue grew about 18% to $656.4 million, and homes sold increased roughly 15% to 5,972. Diluted earnings were $7.17 a share, compared with $6.55, although a one-time $7 million insurance premium refund supplied about $0.70 of that.

Gross Margin contracted to 22.5% from 24.2% under higher input costs, but Backlog expanded $50 million to $348 million. Orders for workforce housing tied to Data Center projects started this quarter, according to the company. Share repurchases totaled about $30 million, leaving $158 million of authorization.

Valuation figures dated Oct 27, 2026, before the move, put Market Value near $4.09 billion and the 52-week range at $443.34 to $713.01.

3. Regeneron Pharmaceuticals: a push above its 52-week high on strong quarterly figures

Regeneron stock has risen 14.21% to $935.14 following third-quarter revenue growth of 36% to $5.1 billion and non-GAAP EPS growth of 70% to $20.07. The company also disclosed that Sanofi (NASDAQ:SNY) will pay $1.0 billion upfront for four long-acting antibodies, plus up to $7.0 billion in later milestones and costs, with profits and costs split evenly.

U.S. net sales of EYLEA HD climbed 62% to $699 million, while total U.S. EYLEA Franchise sales held at $1.1 billion as the original product fell. Cash and marketable securities amounted to roughly $18.9 billion.

Market data from Oct 27, 2026 showed a market value near $81.2 billion and a 52-week high of $859.34, which today's price has now surpassed.

4. AutoNation: adjusted earnings support the rally even as revenue dips

AutoNation has risen 10.73% to $187.51 as third-quarter adjusted EPS of $5.11 slightly outpaced $5.01 from a year earlier. The headline numbers were weaker, with revenue down 0.4% to $7.01 billion, Net Income down 25% to $162.3 million and GAAP diluted EPS falling to $4.87 from $5.65. A reduced share count contributed to the adjusted result.

A record $616.6 million of parts and service Gross Profit sat alongside $15.4 million of AutoNation Finance earnings, up from $1.5 million a year ago. In October the board lifted the buyback authorization by $1.0 billion, leaving $1.4 billion available as of Oct 28, 2026.

No forward guidance accompanied the release. A market value near $5.3 billion, roughly 35% lower over the past year, comes from a snapshot that came before these results.

5. Veralto: a third-quarter beat over its own guidance and a higher full-year range

Veralto's third-quarter adjusted earnings of $1.18 per share cleared the $1.06 to $1.09 range it had guided to in July, and the stock has climbed 8.97% to $113.39. Sales expanded 7.5% to $1.509 billion, core sales advanced 5.1% and adjusted Operating Margin came in at 25.6%.

The company raised its full-year adjusted earnings outlook to $4.49 to $4.52 per share from $4.35 to $4.43. The water analytics and product identification business has put roughly $1.1 billion into four acquisitions this year and repurchased $550 million in stock.

Available valuation figures come from the July report and show a 52-week high of $110.11, a level the current price now exceeds. Those numbers are stale, and the precise release timing tied to today's move has not been confirmed.

High-Priced Gainers Set Side by Side: Spread, Average and Price Distance

Averaging the five percentages gives 12.60% (calculated from the five reported figures). The spread between the top gain of 14.61% and the bottom gain of 8.97% is 5.64 percentage points (calculated), and the leading three finish within 0.40 points of one another (calculated).

Share prices diverge far more than percentages. Regeneron's $935.14 is about 8.25 times Veralto's $113.39 (calculated), so an identical percentage gain yields very different per-share sums.

The catalysts vary in character. Among the catalysts, FedEx Freight combined revenue growth with a guidance raise, Regeneron added a major Partnership payment, Cavco reported record revenue, Veralto beat its own guidance, and AutoNation leaned on adjusted earnings and Buybacks despite lower sales. Several valuation snapshots predate the move.

What to Watch Next: Cavco's Earnings Call, Regeneron's Dated Events and Veralto's Outlook

Cavco has its Earnings Call on Oct 30, 2026, where commentary on input costs and order intake may add detail. FedEx Freight lifted guidance for the period ending Dec 31, 2026 and intends to disclose a Dividend and buyback plan for calendar 2027, subject to board approval.

Regeneron's calendar carries an FDA decision on cemdisiran in generalized myasthenia gravis slated for November 2026, a February 2027 target for odronextamab, a March 2027 Libtayo decision and a quarterly dividend payable Dec 3.

AutoNation and Veralto each look to their fourth-quarter reports, though no dates appear in the source material. Veralto expects fourth-quarter core sales growth of 5.5% to 6.5%, and AutoNation has offered no forward guidance.